Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Avera McKennan Hospital & University Health Center
Orano Med LLC
RasCal Therapeutics, Inc.
Blokhin's Russian Cancer Research Center
University of Nebraska
Eli Lilly and Company
Var2 Pharmaceuticals
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Poitiers University Hospital
Apollomics Inc.
Columbia University
Tempus AI
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Universidade Federal de Pernambuco
Taproot Health
VitaMed Research LLC
Washington University School of Medicine
Second Affiliated Hospital of Guangzhou Medical University
University of Southern California
Eastern Cooperative Oncology Group
Health Clinics Limited
Fudan University
SpeciCare
Jiujiang University Affiliated Hospital
Stanford University
Swiss Cancer Institute
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
Leaf Vertical Inc.
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center
Stanford University
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc